ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
Adicet Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.53−0.04 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $48.68M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -148.3% | -67.6% | |
| Return on assets | – | -31.2% | -56.6% | |
| Current ratio | – | 4.46 | 7.47 | |
| Interest coverage | – | -292.5× | -3392.1× | |
| Diluted shares | – | 0M | 7M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Adicet Bio generated $377.16M from operations and spent $37.15M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$377.16M
Used
$37.15M
Capital expenditure$37.15M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$116.80M
- Cash generatingOperating cash flow above zero-$95.25M
- Return on assets improvedROA up on the prior year-56.5% → -53.0%
- Earnings backed by cashOperating cash flow above net income-$95.25M vs -$116.80M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.29 → 7.47
- No dilutionShare count did not rise5M → 7M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –